Last reviewed · How we verify

Bezlotoxumab Injection — Competitive Intelligence Brief

Bezlotoxumab Injection (Bezlotoxumab Injection) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (toxin-neutralizing). Area: Infectious Disease.

marketed Monoclonal antibody (toxin-neutralizing) Clostridioides difficile toxin B Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Bezlotoxumab Injection (Bezlotoxumab Injection) — The Cooper Health System. Bezlotoxumab is a monoclonal antibody that binds to and neutralizes Clostridioides difficile toxin B, preventing its pathogenic effects on the intestinal epithelium.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bezlotoxumab Injection TARGET Bezlotoxumab Injection The Cooper Health System marketed Monoclonal antibody (toxin-neutralizing) Clostridioides difficile toxin B

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (toxin-neutralizing) class)

  1. The Cooper Health System · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bezlotoxumab Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/bezlotoxumab-injection. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: